Granted Patent
B2
US 11,612,597 · App. 16/905,307 · Granted Mar 28, 2023
Method of treating cancer
Assignee:
Exelixis, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.
Claims (3)
1. A method for treating male patients with castration resistant prostate cancer and osteoblastic bone metastases associated with castration resistant prostate cancer, comprising administering to the male patient a 60 mg, 40 mg, or 20 mg once daily dose of Compound 1:
wherein Compound 1 is administered as the L-malate salt.
2. The method of claim 1 , wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition additionally comprising a pharmaceutically acceptable carrier, excipient, or diluent.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 21, 2023
From: HUSSAIN, MAHA; SMITH, DAVID
To: REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 063049/0058 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 21, 2023
From: REGENTS OF THE UNIVERSITY OF MICHIGAN
To: EXELIXIS, INC.
Reel/Frame 063049/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 22, 2022
From: HUSSAIN, MAHA; SMITH, DAVID
To: REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 061850/0837 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 22, 2022
From: REGENTS OF THE UNIVERSITY OF MICHIGAN
To: EXELIXIS, INC.
Reel/Frame 061850/0912 →
Continuity (5)
Continuation
13876290
Provisional Application
61481671
· May 2, 2011
Provisional Application
61386959
· Sep 27, 2010